Cat. No.: HY-N0419

Quercimeritrin

(Synonyms: Quercetin-7-O-β-D-glucopyranoside)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Quercimeritrin (Quercetin-7-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor (with an IC₅₀ of 79.88 μM against the Saccharomyces cerevisiae enzyme) and a P-gp substrate, with anti-angiogenic and antioxidant activities. Quercimeritrin does not cross the blood-brain barrier and does not inhibit cytochrome P450 enzymes. Quercimeritrin precisely binds to and inhibits the active sites of c-Kit, MMP-2, Aurora-A kinases and α-glucosidase, thereby disrupting target functions. Quercimeritrin effectively regulates postprandial blood glucose and also exhibits significant anti-angiogenic activity, which inhibits endothelial cell proliferation and microvascular growth. Quercimeritrin can be used in the research of diabetes and breast cancer.

For research use only. We do not sell to patients.

Purity: 99.48%
CAS No.: 491-50-9
Formula: C₂₁H₂₀O₁₂
Molecular Weight:464.38

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Quercimeritrin Chemical Structure

CAS No.: 491-50-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

VEGFR2

MMP-2

MMP-9

All MMP Isoforms :

All VEGFR Isoforms :

All Aurora Kinase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
KB	ED₅₀	28 μg/mL Compound: NSC-115917	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 469554]

In Vitro

Quercimeritrin has a high absorption rate in the human intestine, cannot cross the blood-brain barrier, and does not inhibit major CYPs. It is a substrate of P-gp, and fails to meet one of the Ghose rules due to its low lipophilicity^[1].
Quercimeritrin (3.91-500 μM; 10-20 min) potently inhibits α-glucosidase isolated from Saccharomyces cerevisiae, with an IC₅₀ of 79.88 μM, and exhibits a concentration-dependent inhibitory effect^[2].
Quercimeritrin (3.91-500 μM; 10-20 min) weakly inhibits porcine pancreas-derived α-amylase, with an IC₅₀ value greater than 250 μM^[2].
Quercimeritrin (15.6-500 μM) competitively inhibits α-glucosidase from Saccharomyces cerevisiae and α-amylase from porcine pancreas, and exhibits higher binding affinity for α-glucosidase^[2].
Quercimeritrin (10-100 μM; 72 h) inhibits the proliferation of human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner, with a significant inhibitory effect observed at 100 μM^[3].
Quercimeritrin (100 μM; 12 h) cannot effectively inhibit tube formation in human umbilical vein endothelial cells (HUVECs), with an inhibition rate of less than 20%^[3].
Quercimeritrin (100 μM; 6 h) does not inhibit VEGF-induced HUVEC migration in Boyden chamber assays^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[3]

Cell Line:

Human umbilical vein endothelial cell (HUVEC)
Concentration:

10, 100 μM
Incubation Time:

72 h
Result:

Suppressed HUVEC proliferation in a dose-dependent manner at 10-100 μM.
Significantly suppressed HUVEC proliferation at 100 μM.

Cell Migration Assay^[3]

Cell Line:

Human umbilical vein endothelial cell (HUVEC)
Concentration:

100 μM
Incubation Time:

6 h
Result:

Did not suppress VEGF-induced HUVEC migration, with migrated cell numbers similar to the positive control (VEGF alone).

In Vivo

Quercimeritrin (100-200 mg/kg; oral; single dose) significantly inhibits postprandial hyperglycemia in db/db mice, with the 200 mg/kg oral dose reducing glucose AUC_0-t by 24.5% and the 100 mg/kg dose reducing glucose AUC_0-t by 19.0%^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

db/db mice^[2]
Dosage:

100 mg/kg; 200 mg/kg
Administration:

oral; single dose
Result:

Reduced postprandial glucose area under the curve (AUC) by 19.0% to 43.7 mmol/(L*h) compared to the model group (100 mg/kg dose).
Reduced postprandial glucose AUC by 24.5% to 40.7 mmol/(L*h) compared to the model group (200 mg/kg dose).
Resulted in a significantly lower postprandial blood glucose level at 120 minutes than the control and acarbose groups (200 mg/kg dose).

Chemical Information

CAS No. 491-50-9
Appearance Solid
Molecular Weight 464.38
Formula C₂₁H₂₀O₁₂
Color White to yellow
SMILES

OC1=CC=C(C(OC2=C3C(O)=CC(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C2)=C(O)C3=O)C=C1O
Synonyms

Quercetin-7-O-β-D-glucopyranoside
Structure Classification
- Flavonoids
- Flavonols
Initial Source
- Plants
- Compositae
- Endogenous metabolite
- Human Gut Microbiota Metabolites
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL (71.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1534 mL

10.7670 mL

21.5341 mL

5 mM

0.4307 mL

2.1534 mL

4.3068 mL

10 mM

0.2153 mL

1.0767 mL

2.1534 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yırtıcı Ü, et al. Centaurea mersinensis phytochemical composition and multi-dimensional bioactivity properties supported by molecular modeling[J]. Journal of Biomolecular Structure and Dynamics, 2024, 42(5): 2341-2357.

[2]. Guo F, et al. Inhibitory Mechanism of Quercimeritrin as a Novel α-Glucosidase Selective Inhibitor. Foods. 2023;12(18):3415. Published 2023 Sep 13. [Content Brief]

[3]. Matsubara K, et al. Anti-angiogenic activity of quercetin and its derivatives[J]. Letters in Drug Design & Discovery, 2004, 1(4): 329-333.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1534 mL	10.7670 mL	21.5341 mL	53.8352 mL
	5 mM	0.4307 mL	2.1534 mL	4.3068 mL	10.7670 mL
	10 mM	0.2153 mL	1.0767 mL	2.1534 mL	5.3835 mL
	15 mM	0.1436 mL	0.7178 mL	1.4356 mL	3.5890 mL
	20 mM	0.1077 mL	0.5384 mL	1.0767 mL	2.6918 mL
	25 mM	0.0861 mL	0.4307 mL	0.8614 mL	2.1534 mL
	30 mM	0.0718 mL	0.3589 mL	0.7178 mL	1.7945 mL
	40 mM	0.0538 mL	0.2692 mL	0.5384 mL	1.3459 mL
	50 mM	0.0431 mL	0.2153 mL	0.4307 mL	1.0767 mL
	60 mM	0.0359 mL	0.1795 mL	0.3589 mL	0.8973 mL

Quercimeritrin

2 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Quercimeritrin

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Metabolism/Protease Compound Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Glycoside Compound Library

Lipid Compound Library

Medicine Food Homology Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Gut Microbial Metabolite Library

Anti-Blood Cancer Compound Library

Microbial Metabolite Library

Angiogenesis-Related Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Quercimeritrin

All MMP Isoforms

All VEGFR Isoforms

All Aurora Kinase Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Quercimeritrin Related Classifications

HY-N0419 Related Classifications